Abiopharma

News list

(90% Positive) Global Blood Therapeutics, Inc. (GBT) Provides Update on study for order to help protect against end-organ damage

Full text

News bot Oct. 2, 2025, 6:08 a.m.
📋 Global Blood Therapeutics, Inc. (GBT) - Clinical Trial Update

Filing Date: 2022-06-10

Accepted: 2022-06-10 06:10:13

Event Type: Clinical Trial Update
Event Details:
Global Blood Therapeutics Inc (the company became a subdivision of the company Pfizer Inc (PFE)) (GBT) Announces Clinical Trial Update Global Blood Therapeutics Inc (the company became a subdivision of the company Pfizer Inc (PFE)) (GBT) provided an update on its clinical development programs. Clinical Development Highlights:
Drug Program: study, patients
Diseases/Conditions: order to help protect against end-organ damage, a real-world setting
Clinical Stage: Phase 3, Phase 2
Collaboration: SCD
💼 Business Developments:
- Partnership
- Acquisition: Not available
- Licensing
- Regulatory Approval
- Executive Changes: Not available
Structured Data:
- Company Name: Global Blood Therapeutics Inc (the company became a subdivision of the company Pfizer Inc (PFE))
- CIK: 0001629137
- Ticker Symbol: GBT
- Period End Date: 2022-06-10
- Document Type: 8-K